Poniard Pharmaceuticals Net Income

Poniard Pharmaceuticals (PARD) currently reports a net income of $-16M as of September 2011. That compares with $-38M in the prior-year period — up 57.8% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore Poniard Pharmaceuticals's net income history and peer comparisons.

Poniard Pharmaceuticals's net income increased from $-38M to $-16M — a 57.8% year-over-year increase (period ending September 2011). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Poniard Pharmaceuticals's net income of $-16M is lower than the Healthcare sector average of $99B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Poniard Pharmaceuticals reported $-16M in net income as of September 2011. That compares with $-38M in the prior-year period — up 57.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-16M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for Poniard Pharmaceuticals, and consider following PARD for alerts when major investors trade the stock.